Lung Cancer Trials Ask AI to find trials
Active Not RecruitingNot applicableNCT04994795
Official study title

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

Study summary

Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedPredictive models (data collection)

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 21, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Observational

Where is it offered?30 U.S. locations

Locations may change over time.

Who runs it?Sophia Genetics SAS

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Sophia Genetics SAS
Interventions being studied
Other: Predictive models (data collection)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Treatment approach
Immunotherapy→Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Adult ≥18 years old
  • Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage IV)
  • Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR, ALK)
  • Cohort A: Received first line treatment with pembrolizumab monotherapy
  • Cohort B: Received first line treatment with chemotherapy and pembrolizumab combination therapy
  • Cohort C: Received first line treatment with chemotherapy doublet
Reasons someone may not be able to joinExclusion criteria
  • Prior anti-cancer therapy for actual stage IV NSCLC
  • Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first evaluation millimetric imaging)
  • Patients participating in other clinical trials that modify the standard of care

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Holden Comprehensive Cancer Center at University of Iowa Health CareIowa City, Iowa
  • UMASS Memorial HealthWorcester, Massachusetts
  • Mayo ClinicRochester, Minnesota
  • Roswell Park Comprehensive Cancer CenterBuffalo, New York
  • Huntsman Cancer InstituteSalt Lake City, Utah
  • Carbone Comprehensive Cancer Center at University of WisconsinMadison, Wisconsin
  • DASA - Hospital BrasiliaBrasília
  • DASA - Hospital de NiteroiNiterói
  • DASA - Hospital São LucasRio de Janeiro
  • DASA - Hospital Nove De JulhoSão Paulo
  • AC CamargoSão Paulo
  • Sunnybrook Health Sciences Centre TorontoToronto

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 21, 2024. Always confirm current availability with the study team.

View original record ↗